Optimal positioning of storage systems in microgrids based on complex networks centrality measures

We propose a criterion based on complex networks centrality metrics to identify the optimal position of Energy Storage Systems in power networks. To this aim we study the relation between centrality metrics and voltage fluctuations in power grids in presence of high penetration of renewable energy sources and storage systems. For testing purposes we consider two prototypical IEEE networks and we compute the correlation between node centrality (namely Eigenvector, Closeness, Pagerank, Betweenness) and voltage fluctuations in presence of intermittent renewable energy generators and intermittent loads measured from domestic users. We show that the topological characteristics of the power networks are able to identify the optimal positioning of active and reactive power compensators (such as energy storage systems) used to reduce voltage fluctuations according to the common quality of service standards. Results show that, among the different metrics, eigenvector centrality shows a statistically significant exponential correlation with the reduction of voltage fluctuations. This finding confirms the technical know-how for which storage systems are heuristically positioned far from supply reactive nodes. This also represents an advantage both in terms of computational time, and in terms of planning of wide resilient networks, where a careful positioning of storage systems is needed, especially in a scenario of interconnected microgrids where intermittent distributed energy sources (such as wind or solar) are fully deployed

SUSCEPTIBILITY OF Listeria monocytogenes STRAINS ISOLATED FROM FOOD TO ANTIMICROBIAL AGENTS

The objective of this study was to evaluate the susceptibility of 40 L. monocytogenes strains isolated from seafood and processing environments to 19 antibiotics currently used in veterinary and human therapy. Susceptibility tests were performed by the automated system VITEK2. Apart from Penicillin, Ampicillin and Trimethoprim-Sulfamethoxazole, for which clinical breakpoint for Listeria susceptibility testing are defined according to the Clinical and Laboratory Standard Institute (CLSI), in the present study the CLSI criteria for staphylococci were applied. This study shows that isolated L. monocytogenes strains are susceptible to the antibiotics commonly used in veterinary and human listeriosis treatment. Very few strains (7,5%) showed a resistance behaviour towards Oxacillin, whereas a variable pattern was showed for Ciprofloxacin and Moxifloxacin. Moreover, an increase in tetracycline resistance, reported by several authors, can not be confirmed in this study, probably due to the different sources of strains isolation. At last, the VITEK2 system represents a rapid and easy-to-use means for antimicrobial susceptibility test of Listeria monocytogenes. In conclusion, because of the increase of antimicrobial resistance showed by L. monocytogenes, a continuous surveillance of emerging antimicrobial resistance among this pathogen is important to ensure effective treatment of human listeriosis. These data can be used for improve background data on antibiotic resistance of strains isolated from food and food environment, even considering the lack of clinical breakpoint provided by the CLSI

Ex-LDH-based catalysts for CO2 conversion to methanol and dimethyl ether

CO2-derived methanol and dimethyl ether can play a very important role as fuels, energy carriers, and bulk chemicals. Methanol production from CO2 and renewable hydrogen is considered to be one of the most promising pathways to alleviate global warming. In turn, methanol could be subsequently dehydrated into DME; alternatively, one-step CO2 conversion to DME can be obtained by hydrogenation on bifunctional catalysts. In this light, four oxide catalysts with the same Cu and Zn content (Cu/Zn molar ratio = 2) were synthesized by calcining the corresponding CuZnAl LDH systems modified with Zr and/or Ce. The fresh ex-LDH catalysts were characterized in terms of composition, texture, structure, surface acidity and basicity, and reducibility. Structural and acid– base properties were also studied on H2-treated samples, on which specific metal surface area and dispersion of metallic Cu were determined as well. After in situ H2 treatment, the ex-LDH systems were tested as catalysts for the hydrogenation of CO2 to methanol at 250 °C and 3.0 MPa. In the same experimental conditions, CO2 conversion into dimethyl ether was studied on bifunctional catalysts obtained by physically mixing the ex-LDH hydrogenation catalysts with acid ferrierite or ZSM-5 zeolites. For both processes, the effect of the Al/Zr/Ce ratio on the products distribution was investigated

CO2 hydrogenation to methanol with an innovative Cu/Zn/Al/Zr catalyst: Experimental tests and process modeling

In this study, an innovative Cu/Zn/Al/Zr catalyst for the conversion of CO2 and H2 into methanol is tested at laboratory scale (0.5 g of catalyst into a cylindrical fixed bed reactor, with 9.1 mm internal diameter). Fourteen experimental tests are performed under isothermal conditions (T = 250 °C), covering a range of pressure (3.0–7.0 MPa), Gas Hourly Space Velocity (4000–13,000 h-1) and H2/CO2 molar ratio (between 3 and 6) relevant to industrial applications, with or without CO in the feed mixture, with flow-rates ranging between 200 and 650 NmL min-1. Based on the established Graaf’s kinetic model, new kinetic parameters are calibrated and a plug-flow model of the isothermal reactor is implemented and simulated in Aspen Plus. A reasonable agreement between experimental data and calibrated model is achieved, with deviations lower than 10% of the measured flow rates for each species in the product stream. CO2 conversion up to 26% and methanol yields up to 13% are obtained during the test campaign (test run #12). The model represents a valid tool for future research or engineering studies targeting the design and performance assessment of demo/full-scale CO2-to-methanol synthesis processes based on the Cu/Zn/Al/Zr catalyst introduced in this paper

FOOD SAFETY AND PROCESS HYGIENE CRITERIONS ON SHEEP CARCASSES

The hygienic status and the presence of some pathogens (Staphylococcus aureus, Listeria monocytogenes e Salmonella spp.) at slaughterhouses was evaluated in different matrix of sheep and lambs (carcass surface, faeces, fleeces and mesenteric lymph nodes) according to the Com. Reg. (EC) No 2073/2005. The 48% of sheep and 68.9% of lamb sampled carcasses resulted allocated into the marginal category for Aerobic colony count, while the 28% and 42.2% respectively were allocated into unacceptable category for Enterobacteriaceae. S.aureus was isolated more frequently in fleeces (11.5%), carcasses (12.6%) of lambs than sheep. L. monocytogenes was found in fleeces and carcass of two sheep and in faeces of four lambs, while Salmonella spp. was detected only in sheep carcasses of a single plant

Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results

AIMS: To test whether canrenone, an aldosterone receptor antagonist, improves left ventricular (LV) remodelling in NYHA class II heart failure (HF). Aldosterone receptor antagonists improve outcome in severe HF, but no information is available in NYHA class II. METHODS AND RESULTS: AREA IN-CHF is a randomized, double-blind, placebo-controlled study testing canrenone on top of optimal treatment in NYHA class II HF with low ejection fraction (EF) to assess 12-month changes in LV end-diastolic volume (LVEDV). Brain natriuretic peptide (BNP) was also measured. Information was available for 188 subjects on canrenone and 194 on placebo. Left ventricular end-diastolic volume was similarly reduced (-18%) in both arms, but EF increased more (P = 0.04) in the canrenone (from 40% to 45%) than in the placebo arm (from 40-43%). Brain natriuretic peptide (n = 331) decreased more in the canrenone (-37%) than in the placebo arm (-8%; P < 0.0001), paralleling a significant reduction in left atrial dimensions (-4% vs. 0.2%; P = 0.02). The composite endpoint of cardiac death and hospitalization was significantly lower in the canrenone arm (8% vs. 15%; P = 0.02). CONCLUSION: Canrenone on top of optimal treatment for HF did not have additional effects on LVEDV, but it increased EF, and reduced left atrial size and circulating BNP, with potential beneficial effects on outcome. A large-scale randomized study should be implemented to confirm benefits on cardiovascular outcomes in patients with HF in NYHA class I